Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922852 | 0.80 | MEN1 (0.47) | ALDH1A1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL1923366 | 0.78 | ALDH1A1 (0.72) | ALDH1A1MAPTHPGDLMNARAB9A | |
| SCHEMBL1923355 | 0.78 | MEN1 (0.69) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 | |
| SCHEMBL1922849 | 0.77 | MEN1 (0.61) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 | |
| SCHEMBL4020988 | 0.76 | RAB9A (0.70) | ALDH1A1MAPTHPGDTDP1THRB | |
| SCHEMBL1922864 | 0.73 | GFER (0.52) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 | |
| SCHEMBL1923059 | 0.72 | MEN1 (0.52) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 | |
| SCHEMBL1923680 | 0.72 | GFER (0.56) | ALDH1A1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL12156722 | 0.72 | NPC1 (0.58) | ALDH1A1MAPTHPGDLMNARAB9A | |
| SCHEMBL12173382 | 0.72 | MEN1 (0.43) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8049037-B2 | Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof | ALLERGAN, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8049037-B2 | Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof | ALLERGAN, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8049037-B2 | Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof | ALLERGAN, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| EP-2328863-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | Allergan, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | S1PR1, S1PR2, S1PR3 | ALDH1A1 2830/4885MAPT 4426/4885HPGD 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.